@article {El Sherbini625, author = {Mustafa Abdel Hafiz El Sherbini and Maha Mohamed Sallam and Emtiaz Abdel Kawy Shaban and Amr Hassan El-Shalakany}, title = {Diagnostic Value of Serum Kallikrein-Related Peptidases 6 and 10 Versus CA125 in Ovarian Cancer}, volume = {21}, number = {4}, pages = {625--632}, year = {2011}, doi = {10.1097/IGC.0b013e31821283c3}, publisher = {BMJ Specialist Journals}, abstract = {Objectives: To assess the diagnostic value of serum KLK6 and KLK10 in patients with ovarian tumor in comparison to serum CA125.Methods: Based on clinical and sonographic findings, 90 patients were consecutively recruited at the Gynecological Oncology Unit, Ain Shams University Maternity Hospital. Preoperative serum KLK6 and/or KLK10 were determined by enzyme-linked immunosorbent assay technique. The patients{\textquoteright} final diagnoses were those of the histopathological reports.Results: There were 27 malignant versus 63 benign cases. Serum markers{\textquoteright} diagnostic specificity and sensitivity were 80.3/72.7, 56.8/64.0, and 39.53/58.3 for CA125, KLK6, and KLK10, respectively. Combination of CA125 with either of the other 2 markers revealed diagnostic enhancement with KLK10 (85.37/73.00) but not with KLK6 (42.86/86.36).Conclusions: In ovarian cancer, serum KLK6 and KLK10 may have much lower overall sensitivities than serum CA125. However, whereas serum KLK6 may improve the sensitivity of CA125, serum KLK10 may have the highest specificity among the 3 markers.}, issn = {1048-891X}, URL = {https://ijgc.bmj.com/content/21/4/625}, eprint = {https://ijgc.bmj.com/content/21/4/625.full.pdf}, journal = {International Journal of Gynecologic Cancer} }